---
title: "ANVS.US (ANVS.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ANVS.US/news.md"
symbol: "ANVS.US"
name: "ANVS.US"
parent: "https://longbridge.com/en/quote/ANVS.US.md"
datetime: "2026-06-13T13:56:23.993Z"
locales:
  - [en](https://longbridge.com/en/quote/ANVS.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ANVS.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ANVS.US/news.md)
---

# ANVS.US (ANVS.US) — Related News

### [Annovis Bio Regains NYSE Compliance Ahead Of 18-Month Cure Period](https://longbridge.com/en/news/287724562.md)
*2026-05-27T06:15:30.000Z*
> Annovis Bio, Inc. (ANVS) has regained compliance with NYSE listing standards within 12 months, ahead of the 18-month cur

### [Annovis Bio Launches ~$15 Million Stock-and-Warrant Offering Underwritten by Canaccord Genuity](https://longbridge.com/en/news/287114729.md)
*2026-05-20T20:23:01.000Z*
> Annovis Bio has launched a public offering of 7,895,000 shares and warrants underwritten by Canaccord Genuity, aiming to

### [Annovis Bio Announces Offering Of Shares And Warrants To Advance Buntanetap In AD; Stock Down](https://longbridge.com/en/news/287040902.md)
*2026-05-20T09:45:19.000Z*
> Annovis Bio, Inc. (ANVS) has announced a public offering of shares and warrants to fund the clinical development of its 

### [12 Health Care Stocks Moving In Tuesday's After-Market Session](https://longbridge.com/en/news/286969790.md)
*2026-05-19T21:06:03.000Z*
> In Tuesday's after-market session, Co-Diagnostics shares surged 20.8% to $2.38, while Celldex Therapeutics rose 16.05% t

### [Annovis Bio | 8-K: FY2026 Q1 Revenue: USD 0](https://longbridge.com/en/news/286607190.md)
*2026-05-15T20:06:51.000Z*
### [Annovis Bio Prices Registered Direct Offering to Fund Trials](https://longbridge.com/en/news/282330500.md)
*2026-04-10T10:38:38.000Z*
> Annovis Bio Prices Registered Direct Offering to Fund Trials

### [](https://longbridge.com/en/news/282218498.md)
*2026-04-09T14:31:55.000Z*
> Annovis Bio shares are trading lower after the company announced pricing of its $10 million offering of common stock and